Literature DB >> 30475224

IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population.

Annewieke W van den Beld1,2, Olga D Carlson3, Maire E Doyle3, Dimitris Rizopoulos4, Luigi Ferrucci3, Aart Jan van der Lely2, Josephine M Egan3.   

Abstract

Objective Insulin-like growth factor-binding protein-2 (IGFBP-2) concentrations are low in subjects with metabolic syndrome and type 2 diabetes. Intriguingly, recent studies have demonstrated an association between high IGFBP-2 concentrations and increased mortality not only in populations with certain types of cancer, but also in relatively healthy populations. We evaluated the role of IGFBP-2 in relation to BMI and mortality. Design and Participants BMI, insulin sensitivity, insulin-like growth factor 1 (IGF-I) and IGFBP-2 were assessed repeatedly in 539 participants of the Baltimore Longitudinal Study of Aging around the ages of 55, 65 and 75 years. Results IGFBP-2 concentrations positively correlated with insulin sensitivity and inversely with BMI, both at baseline and follow-up. Independent of IGF-I, sex, BMI and insulin sensitivity, circulating IGFBP-2 levels positively correlated with age (P < 0.001). Changes over time in BMI were associated with an inverse correlation in IGFBP-2 concentrations. Furthermore, we found indications of a relationship between low baseline IGFBP-2 levels and mortality. Remarkably, after adjustment for insulin sensitivity, the opposite association was found, as a unit increase of log(IGFBP2) was associated with an increase in the log hazard by 1.43 (95% CI: 0.3-2.6). This accounted for both baseline (P = 0.02) as well as serial (P < 0.001) measurements of IGFBP2. Finally, in this longitudinal study, we found that IGF-I concentrations increased with age (0.82 ± 0.2 (µg/L)/year, P < 0.001). Conclusion This is the first study investigating the relationship between IGFBP-2 levels and age in a longitudinal setting. Serum IGFBP-2 levels increase with age after the age of 50 years and evolve in parallel with insulin sensitivity. IGFBP-2 may therefore be a potential marker for insulin sensitivity. We further show that IGFBP-2 levels can predict mortality in this aging population. However, its predictive value for mortality can only be interpreted in relation to insulin sensitivity. After adjustment for insulin sensitivity, high IGFBP-2 levels are predictive of increased mortality.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30475224      PMCID: PMC6445262          DOI: 10.1530/EJE-18-0422

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  37 in total

1.  Tools & techniques--statistics: Dealing with time-varying covariates in survival analysis--joint models versus Cox models.

Authors:  Dimitris Rizopoulos; Johanna J M Takkenberg
Journal:  EuroIntervention       Date:  2014-06       Impact factor: 6.534

2.  Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes.

Authors:  J Frystyk; C Skjaerbaek; E Vestbo; S Fisker; H Orskov
Journal:  Diabetes Metab Res Rev       Date:  1999 Sep-Oct       Impact factor: 4.876

Review 3.  Growth hormone, exercise, and aging: the future of therapy for the frail elderly.

Authors:  S E Borst; W J Millard; D T Lowenthal
Journal:  J Am Geriatr Soc       Date:  1994-05       Impact factor: 5.562

4.  High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men.

Authors:  Annewieke W van den Beld; Werner F Blum; Michael P Brugts; Joop A M J L Janssen; Diederick E Grobbee; Steven W J Lamberts
Journal:  Eur J Endocrinol       Date:  2012-05-03       Impact factor: 6.664

5.  Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway.

Authors:  Zhuo Li; Stéphanie Miard; Mathieu Laplante; Nahum Sonenberg; Frédéric Picard
Journal:  Mol Cell Endocrinol       Date:  2012-03-03       Impact factor: 4.102

6.  Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study.

Authors:  Pouneh K Fazeli; Elizabeth A Lawson; Rajani Prabhakaran; Karen K Miller; Daniel A Donoho; David R Clemmons; David B Herzog; Madhusmita Misra; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

Review 7.  Clinical studies of IGFBP-2 by radioimmunoassay.

Authors:  W F Blum; N Horn; J Kratzsch; J O Jørgensen; A Juul; D Teale; K Mohnike; M B Ranke
Journal:  Growth Regul       Date:  1993-03

8.  Body weight variability in men: metabolic rate, health and longevity.

Authors:  L Lissner; R Andres; D C Muller; H Shimokata
Journal:  Int J Obes       Date:  1990-04

9.  Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study.

Authors:  Donglei Hu; Ludmila Pawlikowska; Alka Kanaya; Wen-Chi Hsueh; Lisa Colbert; Anne B Newman; Suzanne Satterfield; Clifford Rosen; Steven R Cummings; Tamara B Harris; Elad Ziv
Journal:  J Am Geriatr Soc       Date:  2009-06-03       Impact factor: 5.562

Review 10.  IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?

Authors:  Adam Pickard; Dennis J McCance
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-27       Impact factor: 5.555

View more
  10 in total

1.  Old blood from heterochronic parabionts accelerates vascular aging in young mice: transcriptomic signature of pathologic smooth muscle remodeling.

Authors:  Tamas Kiss; Ádám Nyúl-Tóth; Rafal Gulej; Stefano Tarantini; Tamas Csipo; Derek M Huffman; Anna Csiszar; Zoltan Ungvari; Peter Mukli; Anna Ungvari; Priya Balasubramanian; Andriy Yabluchanskiy; Zoltan Benyo; Shannon M Conley; Jonathan D Wren; Lori Garman
Journal:  Geroscience       Date:  2022-02-05       Impact factor: 7.581

Review 2.  The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases.

Authors:  Fei Song; Xiao-Xia Zhou; Yu Hu; Gang Li; Yan Wang
Journal:  Adv Ther       Date:  2020-12-17       Impact factor: 3.845

3.  Overlap of Peak Growth Activity and Peak IGF-1 to IGFBP Ratio: Delayed Increase of IGFBPs versus IGF-1 in Serum as a Mechanism to Speed up and down Postnatal Weight Gain in Mice.

Authors:  Michael Walz; Luong Chau; Christina Walz; Mandy Sawitzky; Daniela Ohde; Julia Brenmoehl; Armin Tuchscherer; Martina Langhammer; Friedrich Metzger; Christine Höflich; Andreas Hoeflich
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

4.  Effects of gastric sleeve surgery on the serum levels of GH, IGF-1 and IGF-binding protein 2 in healthy obese patients.

Authors:  Khalid Al-Regaiey; Suad Alshubrami; Ibrahim Al-Beeshi; Torki Alnasser; Abdulnasser Alwabel; Hassan Al-Beladi; Omar Al-Tujjar; Abdulrahman Alnasser; Assim A Alfadda; Muhammad Iqbal
Journal:  BMC Gastroenterol       Date:  2020-06-25       Impact factor: 3.067

Review 5.  The Concept of Growth Hormone Deficiency Affecting Clinical Prognosis in IVF.

Authors:  John L Yovich; Sheena L P Regan; Syeda Zaidi; Kevin N Keane
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-04       Impact factor: 5.555

Review 6.  Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance.

Authors:  Hatim Boughanem; Elena M Yubero-Serrano; José López-Miranda; Francisco J Tinahones; Manuel Macias-Gonzalez
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

Review 7.  Multifactorial Mechanism of Sarcopenia and Sarcopenic Obesity. Role of Physical Exercise, Microbiota and Myokines.

Authors:  Jan Bilski; Piotr Pierzchalski; Marian Szczepanik; Joanna Bonior; Jerzy A Zoladz
Journal:  Cells       Date:  2022-01-04       Impact factor: 6.600

8.  Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.

Authors:  Pia Fahlbusch; Birgit Knebel; Tina Hörbelt; David Monteiro Barbosa; Aleksandra Nikolic; Sylvia Jacob; Hadi Al-Hasani; Frederique Van de Velde; Yves Van Nieuwenhove; Dirk Müller-Wieland; Bruno Lapauw; D Margriet Ouwens; Jorg Kotzka
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

9.  Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: A cohort study.

Authors:  Ji Yang; Wenjing Zhou; Yue Wu; Liqian Xu; Yuming Wang; Zherong Xu; Yunmei Yang
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

10.  Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.

Authors:  Agata Wesolowska-Andersen; Caroline A Brorsson; Roberto Bizzotto; Andrea Mari; Andrea Tura; Robert Koivula; Anubha Mahajan; Ana Vinuela; Juan Fernandez Tajes; Sapna Sharma; Mark Haid; Cornelia Prehn; Anna Artati; Mun-Gwan Hong; Petra B Musholt; Azra Kurbasic; Federico De Masi; Kostas Tsirigos; Helle Krogh Pedersen; Valborg Gudmundsdottir; Cecilia Engel Thomas; Karina Banasik; Chrisopher Jennison; Angus Jones; Gwen Kennedy; Jimmy Bell; Louise Thomas; Gary Frost; Henrik Thomsen; Kristine Allin; Tue Haldor Hansen; Henrik Vestergaard; Torben Hansen; Femke Rutters; Petra Elders; Leen t'Hart; Amelie Bonnefond; Mickaël Canouil; Soren Brage; Tarja Kokkola; Alison Heggie; Donna McEvoy; Andrew Hattersley; Timothy McDonald; Harriet Teare; Martin Ridderstrale; Mark Walker; Ian Forgie; Giuseppe N Giordano; Philippe Froguel; Imre Pavo; Hartmut Ruetten; Oluf Pedersen; Emmanouil Dermitzakis; Paul W Franks; Jochen M Schwenk; Jerzy Adamski; Ewan Pearson; Mark I McCarthy; Søren Brunak
Journal:  Cell Rep Med       Date:  2022-01-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.